Home >
in Vitro
Antibody Drug
Evaluation
Evaluation
Antibody drugs represented by immune checkpoint inhibitors have become a major focus in innovative drug development. During antibody drug discovery, in vitro efficacy evaluation models play an essential role in accelerating antibody discovery, screening, and optimization.
Based on target mechanisms, Jotbody has systematically developed robust cell-based efficacy models for tumor surface antigens, inhibitory immune checkpoints, co-stimulatory immune checkpoints, and other immune regulatory targets. These models support high-quality and efficient screening of candidate antibodies at the cellular efficacy level.
Based on target mechanisms, Jotbody has systematically developed robust cell-based efficacy models for tumor surface antigens, inhibitory immune checkpoints, co-stimulatory immune checkpoints, and other immune regulatory targets. These models support high-quality and efficient screening of candidate antibodies at the cellular efficacy level.
Highlights
01
Diverse Tumor Target Coverage
Evaluate a broad range of oncology therapeutic targets and drug mechanisms with ease.
02
Comprehensive In Vitro Evaluation System
100+ target-specific cell lines, 20+ reporter gene cell systems, high-precision instruments, and a complete in vitro evaluation workflow.
03
Rich Primary Cell Models
A wide range of human and mouse primary cell resources to better recapitulate in vivo mechanisms in vitro.
04
High-Success Customized Development
Customized multidimensional efficacy evaluation systems can be developed based on target mechanisms.
05
High-Standard Quality System
Efficacy models are evaluated across linearity, precision, accuracy, stability, and other key parameters to ensure higher-quality results.
Comprehensive In Vitro Evaluation System
Jotbody’s in vitro efficacy evaluation platform offers dozens of multidimensional, integrated artificial efficacy evaluation systems. Covering workflows from cell sorting to induced differentiation, from flow cytometry-based cell screening to in vitro functional screening, the platform supports a wide range of applications and meets diverse evaluation needs across antigen-antibody binding, signaling pathways, cellular functions, and more.
| Type | Applications |
|---|---|
| Primary cell sorting & induction |
Human primary cell isolation Mouse primary cell isolation Primary cell induction (Naïve T, Th1/2/17, Treg, Macrophage, Dendritic cell, etc) |
| Cell-based FACS screening |
Antibody binding screening Antibody blocking screening Antibody competition assay Antibody epitope binning assay |
| In vitro functional screening |
T cell co-stimulation / PBMC activation Cell Proliferation/Suppression ADCP / Phagocytosis / ADCC / CDC / MLR Treg suppression assay / Internalization / Inflammatory assay Apoptosis assay / Chemotaxis / Tube formation assay |
| Luciferase screening |
PD-1 / PD-L1 luciferase screening LAG3 / MHCII luciferase screening TIGIT / CD155 luciferase screening CD40 / CD40L luciferase screening TGF-β / TGFβ-RII luciferase screening VEGF / VEGFR luciferase screening IL33 / ST2 luciferase screening |
Table 1. In Vitro Evaluation System
* Rapid custom model development services are available. Please contact us for more information.
Diverse Cell-Based Efficacy Models
Tumor- and immune disease-related targets can be classified by mechanism of action. For tumor-associated antigens, inhibitory immune checkpoint inhibitors, co-stimulatory immune checkpoint modulators, and other immune regulatory factors, corresponding cell-based experimental models are available to support reliable efficacy evaluation.
| Type | Models | Type | Models |
|---|---|---|---|
|
TSA (Tumor specific antigen) |
Antibody-dependent cell cytotoxicity Complement-dependent cytotoxicity Antibody-mediated internalization Antibody-mediated direct killing |
IIC (Inhibitory Immunecheckpoint) |
PBMC activation Mixed lymphocyte reaction Cell proliferation Cell apoptosis |
|
CIC (Co-stimulatory Immunecheckpoint) |
T cell co-stimulation Cell proliferation Cell surface marker detection Cytokine release assessment |
OIM (Other ImmuneModulator) |
Pro-inflammatory assessment Phagocytosis Angiogenesis Chemotaxis |
Table 2. Cell-Based Experimental Models for Different Target Types
Stable and Efficient Reporter Gene Evaluation Models
As shown in Table 3, Jotbody has established dozens of artificial reporter gene models for efficacy evaluation, helping make your drug evaluation process more stable and efficient.
| Type | Target | Screening type |
|---|---|---|
|
Immune checkpoints |
PD-1 / PD-L1 | Antagonistic antibody |
| CD155 / TIGIT | Antagonistic antibody | |
| LAG3 / MHCII | Antagonistic antibody | |
| CD40L / CD40 | Agonistic antibody | |
|
Other immune modulator |
TGF-β / TGF-β-RII | Neutralizing antibody |
| IL-33 / ST-2 | Neutralizing antibody | |
| VEGF / VEGFR2 | Neutralizing antibody |
Table 3. Jotbody In Vitro Efficacy Reporter Gene Screening Models*
* For more information about additional in vitro efficacy screening models, please contact a Jotbody representative.
Valuable Human Primary Cell Evaluation Models
Jotbody’s human primary cell screening system uses Miltenyi Biotec cell separation technology to obtain high-quality human primary cells.
These stable and reliable human primary cell evaluation models help generate more convincing data.
These stable and reliable human primary cell evaluation models help generate more convincing data.
| Cell Type | Target | Assay type |
|---|---|---|
|
PBMC CD4+T CD8+T Monocyte |
TAA | ADCC |
| TAA, TSA | CDC | |
| PD-1 / PD-L1 | MLR | |
| CD47, CD24 | Phagocytose | |
| PD-1 / PD-L1 / CTLA-4 | PBMC activation |
Table 4. Jotbody In Vitro Human Primary Cell Screening Models
Cell Models and Cell Biology Experiments
-
1. Respiratory Disease Models:
Including the RAW264.7 inflammatory cell model and the NCI-H292 airway hypersecretion (MUC5AC) model. -
2. Tumor Cell Models:
lung cancer (3 types including A549); melanoma (B16); colorectal cancer (5 types including SW480 and HCT116); breast cancer (5 types including MCF-7 and MDA-MB-231); liver cancer (4 types including HepG2); cervical cancer (HeLa). - 3. Skin-Related (Cosmetic) In Vitro Evaluation: dermatitis and psoriasis models (RAW264.7, HaCaT); moisturization; photoaging; free radical scavenging; etc.
-
4. Neurological Models:
cerebral hemorrhage; ischemia/reoxygenation injury. -
5. Bioavailability Evaluation:
Caco-2 cell model; MDCK cell model. -
6. Aging Model:
NIH3T3 cellular senescence model.
Service Scope
| Service | Service Content | Client Provides | Deliverables | Timeline |
|---|---|---|---|---|
| In Vitro Efficacy Method Development | Develop target-specific in vitro efficacy evaluation models |
1. Target antibody 2. Mechanism of action |
Validated efficacy evaluation system | 4–8 weeks |
| In Vitro Efficacy Sample Testing | Evaluate the in vitro efficacy of candidate molecules |
1. Target antibody 2. Candidate molecule |
Candidate molecule efficacy evaluation report | 1–2 weeks |
Service List
| Category | Subcategory |
|---|---|
| 1. Primary Cell Isolation | 1.1 Human / Mouse CD3+ Cells |
| 1.2 Human / Mouse CD4+ Cells | |
| 1.3 Human / Mouse CD8+ Cells | |
| 1.4 Human / Mouse CD14+ Cells | |
| 1.5 Human CD33+ Cells | |
| 1.6 Human Treg Cells | |
| 2. Primary Cell Induction | 2.1 Macrophages |
| 2.2 Dendritic Cells | |
| 3. Flow Cytometry Screening | 3.1 Affinity |
| 3.2 Blocking | |
| 3.3 Competition | |
| 3.4 Epitope Binning | |
| 4. Luciferase Reporter System | 4.1 PD-1 / PD-L1 |
| 4.2 PD-1 / PD-L2 | |
| 4.3 LAG3 / MHCII | |
| 4.4 TIGIT / CD155 | |
| 4.5 PVRIG / PVRL2 | |
| 4.6 CD40 / CD40L | |
| 4.7 TGFβ2 / TGFβRII | |
| 4.8 VEGF / VEGFR | |
| 4.9 IL-33 / ST2nM | |
| 4.10 IL-23 / IL-23R | |
| 4.11 CD3 / CD3L | |
| 4.12 4-1BB | |
| 4.13 LILRB1 / HLA-G | |
| 4.14 LILRB2 / HLA-G | |
| 4.15 TNFα / TNFR2 | |
| 4.16 ADCC | |
| 4.17 ADCP | |
| 4.18 Phosphorylation |
| Category | Subcategory |
|---|---|
| 5. Cytotoxicity | 5.1 ADCC |
| 5.2 CDC | |
| 5.3 ADCP | |
| 5.4 Complement-Dependent Killing | |
| 5.5 Antibody-Mediated Direct Killing | |
| 6. Antibody Internalization Detection | 6.1 Fab-Zap Assay |
| 6.2 Dual-Fluorescence Quenching Assay | |
| 6.3 ADC | |
| 7. Co-Stimulatory Immune Checkpoint Assays | 7.1 Cell Co-Stimulation – 41BB |
| 7.2 Cell Co-Stimulation – OX40 | |
| 7.3 Cell Proliferation / Suppression | |
| 7.4 CD40 / CD40L | |
| 7.5 IL-2 Factor Detection | |
| 7.6 IFN-γ Factor Detection | |
| 7.7 TNF-α Factor Detection | |
| 8. Inhibitory Immune Checkpoint Assays | 8.1 PBMC Activation |
| 8.2 NK Cell Activation | |
| 8.3 Mixed Lymphocyte Reaction | |
| 8.4 Apoptosis | |
| 9. Other Immune-Related OIM Assays | 9.1 Neutralization of TGF-β |
| 9.2 Neutralization of IL-17 | |
| 9.3 Neutrophil Chemotaxis | |
| 9.4 STAT3 Phosphorylation | |
| 9.5 STAT5 Phosphorylation | |
| 9.6 STAT6 Phosphorylation | |
| 9.7 Tie2 Phosphorylation | |
| 9.8 Enzymatic Activity Assay | |
| 10. Custom Development | 10.1 Development Based on Patents |
| 10.2 Development Based on Literature | |
| 10.3 Development Based on Mechanism of Action |